Nasus Pharma Ltd. (NSRX) Stock

Healthcare · Drug Manufacturers - General · Member of Other US Stocks

Nasus Pharma Ltd. (NSRX) closed at USD 3.18 on 2026-10-14, a change of -62.1 % over the past year, with a market capitalization of USD 37.07M.

Nasus Pharma Ltd. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Nasus Pharma Ltd. key figures

Previous close

USD 3.18 (2026-10-14)

1-year change

-62.1 %

Market cap

USD 37.07M

Enterprise value

USD 25.35M

P/E ratio (trailing)

-2.64

P/E ratio (forward)

n/a

EPS (trailing)

-1.20

EPS (forward)

n/a

PEG ratio

n/a

Price to book

3.37

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

4.24

Employees

7

Analyst consensus (third-party)

buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Nasus Pharma Ltd.

Nasus Pharma Ltd., a clinical-stage specialty pharmaceutical company focused on the development of intranasal drugs to treat emergency medical conditions. It offers Powder-Based Intranasal (PBI) products to address acute medical conditions and public health threats. The company's products include NS002, Intranasal Epinephrine for assisting in severe allergic reaction emergency situations and NS001, an Intranasal Naloxone powder nasal spray for the treatment of opioid overdose. Nasus Pharma Ltd. was incorporated in 2019 and is based in Tel Aviv-Yafo, Israel.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Nasus Pharma Ltd. and compare it with other stocks.